Literature DB >> 12946023

Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy.

Thomas C Thannickal1, Jerome M Siegel, Robert Nienhuis, Robert Y Moore.   

Abstract

Human narcolepsy is correlated with a greatly reduced number of hypocretin (orexin) containing neurons and axons, and an elevated level of hypothalamic gliosis. We now report that the percentage loss of Hcrt cells and percentage elevation of GFAP staining are variable across forebrain and brain-stem nuclei, and are maximal in the posterior and tuberomammillary hypothalamic region. Regional gliosis and percent loss of hypocretin axons in narcoleptics are not correlated with regional hypocretin cell soma density in normals or with regional percent soma loss in narcoleptics. Rather they are independently and strongly correlated with the regional density of hypocretin axons and the message density for hypocretin receptor 2, as quantified in the rat. These results are consistent with the hypotheses that the loss of hypocretin function in narcolepsy results from a cytotoxic or immunologically mediated attack focused on hypocretin receptor 2 or an antigen anatomically linked to hypocretin receptor 2, and that this process is intensified in regions of high axonal density.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946023     DOI: 10.1111/j.1750-3639.2003.tb00033.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  39 in total

1.  The injection of hypocretin-1 into the nucleus pontis oralis induces either active sleep or wakefulness depending on the behavioral state when it is administered.

Authors:  Mingchu Xi; Michael H Chase
Journal:  Sleep       Date:  2010-09       Impact factor: 5.849

2.  Behavioral correlates of activity in identified hypocretin/orexin neurons.

Authors:  Boris Y Mileykovskiy; Lyudmila I Kiyashchenko; Jerome M Siegel
Journal:  Neuron       Date:  2005-06-02       Impact factor: 17.173

Review 3.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

4.  Narcolepsy and influenza vaccination-induced autoimmunity.

Authors:  S Sohail Ahmed; Lawrence Steinman
Journal:  Ann Transl Med       Date:  2017-01

5.  Sleep-stage transitions during polysomnographic recordings as diagnostic features of type 1 narcolepsy.

Authors:  Julie Anja Engelhard Christensen; Oscar Carrillo; Eileen B Leary; Paul E Peppard; Terry Young; Helge Bjarrup Dissing Sorensen; Poul Jennum; Emmanuel Mignot
Journal:  Sleep Med       Date:  2015-07-07       Impact factor: 3.492

6.  Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.

Authors:  A Crocker; R A España; M Papadopoulou; C B Saper; J Faraco; T Sakurai; M Honda; E Mignot; T E Scammell
Journal:  Neurology       Date:  2005-09-14       Impact factor: 9.910

7.  Greatly increased numbers of histamine cells in human narcolepsy with cataplexy.

Authors:  Joshi John; Thomas C Thannickal; Ronald McGregor; Lalini Ramanathan; Hiroshi Ohtsu; Seiji Nishino; Noriaki Sakai; Akhiro Yamanaka; Carly Stone; Marcia Cornford; Jerome M Siegel
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

8.  The diagnostic value of power spectra analysis of the sleep electroencephalography in narcoleptic patients.

Authors:  Julie Anja Engelhard Christensen; Emil Gammelmark Schreiner Munk; Paul E Peppard; Terry Young; Emmanuel Mignot; Helge Bjarrup Dissing Sorensen; Poul Jennum
Journal:  Sleep Med       Date:  2015-09-15       Impact factor: 3.492

9.  Correlates to Problem Behaviors in Pediatric Narcolepsy: A Pilot Study.

Authors:  Althea Robinson Shelton; Beth Malow
Journal:  J Clin Sleep Med       Date:  2017-12-15       Impact factor: 4.062

10.  Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy.

Authors:  Giuseppe Plazzi; Francesca Poli; Christian Franceschini; Antonia Parmeggiani; Piero Pirazzoli; Filippo Bernardi; Emmanuel Mignot; Alessandro Cicognani; Pasquale Montagna
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.